VPPM — ProFund VP Pharmaceuticals
Data updated: 2026-08-28
VPPM — ProFund VP Pharmaceuticals. United States Small Cap Blend / Core Health Care Equity · $11.52M AUM. Holdings, fees, performance and SEC filings.
VPPM Fund Overview
VPPM — ProFund VP Pharmaceuticals is a US mutual fund managed by ProFunds, categorised as United States Small Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: ProFunds
- Category: United States Small Cap Blend / Core Health Care Equity
- Assets under management: $11.52M
- 1-year return: 62.2%
- Ticker: VPPM
- SEC CIK: 0001039803
- SEC series ID: S000003975
- Share class ID: C000011102
VPPM Investment Objective and Strategy
ProFund VP Pharmaceuticals describes its objective and strategy as follows, from its latest prospectus filed with the SEC by ProFunds.
Investment objective
ProFund VP Pharmaceuticals (the Fund) seeks investment results, before fees and expenses, that track the performance of the S&P Pharmaceuticals Select Industry Index (the Index).
Principal investment strategy
The Fund invests in securities that ProFund Advisors believes, in combination, should track the performance of the Index. The Index is designed to measure the performance of pharmaceuticals companies included in the S&P Total Market Index. The S&P Total Market Index is designed to track the broad equity market listed and domiciled in the U.S. The Index includes companies in the pharmaceuticals sub-industry according to the Global Industry Classification Standard (GICS). These companies are then weighted using an equal weight methodology with liquidity adjustments. The Indexs composition and the assigned weights are reevaluated every September with additional weight adjustments in March, June, and December. The Index is constructed and maintained by S&P Dow Jones Indices LLC. More information about the Index can be found using the Bloomberg ticker symbol SPSIPH.
Under normal circumstances, the Fund will invest at least 80% of its total assets in components of the Index or in instruments with similar economic characteristics. The Fund will invest principally in the securities listed below. ? Equity Securities Common stock issued by public companies. ProFund Advisors uses a mathematical approach to investing in which it determines the type, quantity and mix of investment positions that it believes, in combination, the Fund should hold to produce returns consistent with its investment objective. The Fund seeks to remain fully invested at all times in financial instruments that, in combination, provide exposure consistent with the investment objective, without regard to market conditions, trends or direction. The Fund may also invest in or gain exposure to only a representative sample of the securities in the Index or to securities not contained in the Index or in financial instruments, with the intent of obtaining exposure consistent with the investment objective.
Please see Investment Objectives, Principal Investment Strategies and Related Risks in the Funds Prospectus for additional details.
VPPM Holdings
Top 10 holdings of ProFund VP Pharmaceuticals by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Definium Therapeutics, Inc. | 2.99% |
| Mbx Biosciences, Inc. | 2.64% |
| Alumis, Inc. | 2.08% |
| Ataibeckley, Inc. | 2.06% |
| Trevi Therapeutics, Inc. | 2.06% |
| Enliven Therapeutics, Inc. | 2.03% |
| Amylyx Pharmaceuticals, Inc. | 1.97% |
| Veradermics, Inc. | 1.96% |
| Ligand Pharmaceuticals, Inc. | 1.89% |
| Nuvation Bio, Inc. | 1.83% |
VPPM Portfolio Allocation
Asset-class allocation of ProFund VP Pharmaceuticals by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 96.9% |
| Cash & Equivalents | 4.8% |
VPPM Performance
Total returns for VPPM (as of 2026-10-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 17.8% |
| 1 year | 62.2% |
| 3 years (annualised) | 16.9% |
| 5 years (annualised) | 8.5% |
VPPM Risk Information
Risk metrics for VPPM, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 21.1%
VPPM Costs and Fees
VPPM costs about $168 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.68%
- Gross expense ratio: 1.69%
- Portfolio turnover: 143%
- Brokerage commissions: 3.51 bps of average net assets (SEC N-CEN)
VPPM Cashflows
Over the 12 months to 2026-06, ProFund VP Pharmaceuticals had net inflows of $772.60K, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-06 | $1.70M |
| 2026-05 | $106.44K |
| 2026-04 | −$989.63K |
| 2026-03 | −$3.85K |
| 2026-02 | $28.86K |
| 2026-01 | $77.34K |
VPPM Debt Constituents
No individual debt constituents are reported in ProFund VP Pharmaceuticals's latest SEC N-PORT filing.
VPPM Prospectus and SEC Filings
Official ProFund VP Pharmaceuticals filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2026-04-28
- Prospectus (485BPOS) — filed 2025-04-25
- Prospectus (485BPOS) — filed 2024-04-26
- Portfolio holdings (N-PORT) — filed 2026-08-28
- Portfolio holdings (N-PORT) — filed 2026-05-20
- Portfolio holdings (N-PORT) — filed 2026-02-19
- Annual census (N-CEN) — filed 2026-03-12
- Annual census (N-CEN) — filed 2025-03-14
Related Funds
Other United States Small Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.